Home>>Signaling Pathways>> Ubiquitination/ Proteasome>> Autophagy>>Autophinib

Autophinib

Catalog No.GC19453

Autophinib is a potent autophagy inhibitor

Products are for research use only. Not for human use. We do not sell to patients.

Autophinib Chemical Structure

Cas No.: 1644443-47-9

Size Price Stock Qty
10mM (in 1mL DMSO)
$103.00
In stock
2mg
$54.00
In stock
5mg
$81.00
In stock
10mg
$144.00
In stock
50mg
$408.00
In stock
100mg
$653.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Autophinib is a potent, selective autophagy inhibitor with IC50s of 90 nM and 40 nM for starvation- and Rapamycin-induced autophagy, respectively. Autophinib is also an ATP competitive Vacuolar Protein Sorting 34 (VPS34) inhibitor with an IC50 of 19 nM. Autophinib inhibits autophagy induced by starvation or Rapamycin by targeting VPS34[1].

Autophinib (0.01-1 μM) inhibits LC3 lipidation to form LC3-II in a dose-dependent manner in starved MCF7-LC3 cells. Consistent with inhibition of autophagic flux, Autophinib also inhibits p62 degradation by autophagy dose-dependently in MCF7-LC3 cells[1].Autophinib enhances cell death (EC50 of 264 nM) of starved cells as compared to fed cells, which occurred via the induction of apoptosis (EC50 of 234 nM) in MCF7 cells[1].

References:
[1]. Robke L, et al. Phenotypic Identification of a Novel Autophagy Inhibitor Chemotype Targeting Lipid Kinase VPS34. Angew Chem Int Ed Engl. 2017 Jul 3;56(28):8153-8157.

Reviews

Review for Autophinib

Average Rating: 5 ★★★★★ (Based on Reviews and 2 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Autophinib

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.